Nicholas Cost
Concepts (400)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 73 | 2026 | 419 | 17.750 |
Why?
| | Wilms Tumor | 40 | 2026 | 91 | 11.960 |
Why?
| | Testicular Neoplasms | 24 | 2026 | 108 | 8.860 |
Why?
| | Nephrectomy | 39 | 2026 | 172 | 7.380 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 15 | 2026 | 76 | 5.860 |
Why?
| | Lymph Node Excision | 13 | 2024 | 174 | 3.830 |
Why?
| | Carcinoma, Renal Cell | 18 | 2025 | 231 | 3.780 |
Why?
| | Rhabdoid Tumor | 7 | 2026 | 99 | 2.980 |
Why?
| | Lower Urinary Tract Symptoms | 4 | 2026 | 62 | 2.880 |
Why?
| | Neoplasm Staging | 31 | 2026 | 1488 | 2.530 |
Why?
| | Lymph Nodes | 9 | 2023 | 511 | 2.440 |
Why?
| | Child | 107 | 2026 | 22693 | 2.260 |
Why?
| | Urology | 8 | 2024 | 63 | 2.230 |
Why?
| | Child, Preschool | 76 | 2026 | 11913 | 2.100 |
Why?
| | Urinary Bladder | 5 | 2024 | 194 | 2.060 |
Why?
| | Medical Oncology | 7 | 2023 | 345 | 1.970 |
Why?
| | Urodynamics | 4 | 2025 | 44 | 1.890 |
Why?
| | Orchiectomy | 8 | 2023 | 72 | 1.890 |
Why?
| | Laparoscopy | 12 | 2024 | 487 | 1.840 |
Why?
| | Adolescent | 77 | 2026 | 22557 | 1.810 |
Why?
| | Infant | 64 | 2026 | 10114 | 1.770 |
Why?
| | Rhabdomyosarcoma | 5 | 2022 | 65 | 1.750 |
Why?
| | Hydronephrosis | 6 | 2019 | 36 | 1.730 |
Why?
| | Urinary Tract | 3 | 2025 | 47 | 1.710 |
Why?
| | Vincristine | 3 | 2024 | 148 | 1.610 |
Why?
| | Lymphatic Metastasis | 12 | 2022 | 335 | 1.540 |
Why?
| | Urologic Surgical Procedures | 8 | 2019 | 126 | 1.490 |
Why?
| | Urologists | 3 | 2017 | 20 | 1.480 |
Why?
| | Humans | 166 | 2026 | 146342 | 1.430 |
Why?
| | Male | 115 | 2026 | 73396 | 1.430 |
Why?
| | Urologic Neoplasms | 4 | 2017 | 31 | 1.430 |
Why?
| | Radiotherapy | 2 | 2025 | 209 | 1.390 |
Why?
| | Prognosis | 28 | 2026 | 4351 | 1.340 |
Why?
| | Kidney Pelvis | 6 | 2015 | 22 | 1.340 |
Why?
| | Robotics | 6 | 2015 | 89 | 1.320 |
Why?
| | Pelvic Neoplasms | 3 | 2025 | 24 | 1.310 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2022 | 99 | 1.310 |
Why?
| | Pediatrics | 7 | 2025 | 1124 | 1.220 |
Why?
| | Practice Patterns, Physicians' | 6 | 2024 | 1408 | 1.200 |
Why?
| | Urinary Bladder Neoplasms | 4 | 2021 | 259 | 1.160 |
Why?
| | Organ Sparing Treatments | 4 | 2023 | 37 | 1.130 |
Why?
| | Ureteral Obstruction | 5 | 2015 | 62 | 1.060 |
Why?
| | Doxorubicin | 2 | 2021 | 416 | 1.050 |
Why?
| | Urinary Bladder Diseases | 2 | 2019 | 18 | 1.030 |
Why?
| | Female | 91 | 2026 | 79499 | 1.030 |
Why?
| | Kidney | 9 | 2023 | 1498 | 1.020 |
Why?
| | Retrospective Studies | 49 | 2026 | 17438 | 0.980 |
Why?
| | Tumor Burden | 7 | 2025 | 326 | 0.970 |
Why?
| | Neoplasms | 8 | 2026 | 2954 | 0.940 |
Why?
| | Young Adult | 37 | 2026 | 14330 | 0.930 |
Why?
| | Kidney Diseases, Cystic | 3 | 2021 | 24 | 0.870 |
Why?
| | Rhabdomyosarcoma, Embryonal | 2 | 2022 | 16 | 0.870 |
Why?
| | Nephrons | 9 | 2023 | 23 | 0.850 |
Why?
| | Biopsy | 6 | 2024 | 1075 | 0.830 |
Why?
| | Ribonuclease III | 3 | 2021 | 44 | 0.820 |
Why?
| | Mixed Tumor, Malignant | 1 | 2023 | 4 | 0.810 |
Why?
| | Sarcoma, Clear Cell | 3 | 2025 | 10 | 0.800 |
Why?
| | Sertoli-Leydig Cell Tumor | 3 | 2021 | 8 | 0.790 |
Why?
| | DEAD-box RNA Helicases | 3 | 2021 | 90 | 0.780 |
Why?
| | Surgeons | 4 | 2025 | 351 | 0.770 |
Why?
| | Hypospadias | 4 | 2011 | 34 | 0.760 |
Why?
| | Seminoma | 3 | 2021 | 20 | 0.750 |
Why?
| | Disease-Free Survival | 8 | 2025 | 778 | 0.740 |
Why?
| | Age Factors | 14 | 2025 | 3347 | 0.730 |
Why?
| | Urologic Surgical Procedures, Male | 4 | 2018 | 33 | 0.730 |
Why?
| | Sarcoma | 3 | 2024 | 209 | 0.730 |
Why?
| | Leydig Cell Tumor | 3 | 2021 | 8 | 0.720 |
Why?
| | Spermatic Cord Torsion | 2 | 2013 | 7 | 0.720 |
Why?
| | Surgical Oncology | 2 | 2025 | 30 | 0.700 |
Why?
| | Cryptorchidism | 2 | 2019 | 15 | 0.690 |
Why?
| | Paraganglioma | 1 | 2022 | 65 | 0.690 |
Why?
| | Pulmonary Blastoma | 1 | 2021 | 8 | 0.660 |
Why?
| | Tomography, X-Ray Computed | 10 | 2026 | 2786 | 0.660 |
Why?
| | Lung Neoplasms | 5 | 2026 | 2675 | 0.660 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 135 | 0.650 |
Why?
| | Pheochromocytoma | 2 | 2019 | 67 | 0.640 |
Why?
| | Survival Rate | 14 | 2026 | 2092 | 0.640 |
Why?
| | Follow-Up Studies | 19 | 2026 | 5439 | 0.640 |
Why?
| | Molecular Targeted Therapy | 3 | 2025 | 447 | 0.620 |
Why?
| | Cancer Survivors | 2 | 2026 | 348 | 0.620 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2019 | 3 | 0.610 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2024 | 1160 | 0.610 |
Why?
| | Infant, Newborn | 11 | 2023 | 6460 | 0.600 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 2 | 2017 | 5 | 0.590 |
Why?
| | Cystectomy | 1 | 2019 | 46 | 0.590 |
Why?
| | Smooth Muscle Myosins | 1 | 2019 | 7 | 0.590 |
Why?
| | Muscle Relaxation | 1 | 2019 | 28 | 0.580 |
Why?
| | Neoplasm Invasiveness | 7 | 2017 | 504 | 0.580 |
Why?
| | Myosin Light Chains | 1 | 2019 | 29 | 0.580 |
Why?
| | Treatment Outcome | 28 | 2026 | 11821 | 0.570 |
Why?
| | Retroperitoneal Space | 2 | 2024 | 19 | 0.570 |
Why?
| | Diagnostic Imaging | 3 | 2022 | 340 | 0.560 |
Why?
| | Fertility Preservation | 3 | 2024 | 57 | 0.560 |
Why?
| | Surveys and Questionnaires | 4 | 2024 | 6073 | 0.550 |
Why?
| | Catheterization | 1 | 2019 | 179 | 0.550 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2018 | 64 | 0.540 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2026 | 1998 | 0.540 |
Why?
| | Risk Assessment | 12 | 2026 | 3712 | 0.540 |
Why?
| | Health Care Surveys | 2 | 2017 | 541 | 0.540 |
Why?
| | von Hippel-Lindau Disease | 1 | 2018 | 12 | 0.540 |
Why?
| | Testicular Diseases | 1 | 2018 | 6 | 0.540 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 141 | 0.540 |
Why?
| | Specimen Handling | 1 | 2019 | 178 | 0.530 |
Why?
| | Calculi | 1 | 2018 | 15 | 0.530 |
Why?
| | Neoadjuvant Therapy | 4 | 2021 | 475 | 0.530 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2012 | 530 | 0.520 |
Why?
| | Orchiopexy | 3 | 2019 | 6 | 0.520 |
Why?
| | Prospective Studies | 12 | 2026 | 8123 | 0.510 |
Why?
| | Conservative Treatment | 1 | 2018 | 45 | 0.510 |
Why?
| | Cause of Death | 3 | 2026 | 456 | 0.510 |
Why?
| | Kaplan-Meier Estimate | 6 | 2019 | 970 | 0.500 |
Why?
| | Radiation Exposure | 1 | 2017 | 62 | 0.500 |
Why?
| | Kidney Medulla | 1 | 2016 | 28 | 0.500 |
Why?
| | Cytodiagnosis | 1 | 2017 | 31 | 0.500 |
Why?
| | Critical Pathways | 1 | 2018 | 104 | 0.500 |
Why?
| | Frozen Sections | 1 | 2017 | 23 | 0.490 |
Why?
| | Angiomyolipoma | 1 | 2016 | 21 | 0.490 |
Why?
| | SEER Program | 7 | 2026 | 233 | 0.480 |
Why?
| | Teratoma | 2 | 2017 | 121 | 0.470 |
Why?
| | Muscle Contraction | 1 | 2019 | 438 | 0.470 |
Why?
| | Tuberous Sclerosis | 1 | 2016 | 56 | 0.460 |
Why?
| | Granuloma, Plasma Cell | 1 | 2015 | 12 | 0.460 |
Why?
| | Postoperative Care | 1 | 2018 | 301 | 0.460 |
Why?
| | Survivorship | 2 | 2026 | 62 | 0.440 |
Why?
| | Pediatricians | 1 | 2016 | 120 | 0.440 |
Why?
| | Survival Analysis | 5 | 2019 | 1378 | 0.440 |
Why?
| | Adult | 26 | 2026 | 41087 | 0.440 |
Why?
| | Glomerular Filtration Rate | 4 | 2018 | 745 | 0.440 |
Why?
| | Abdominal Neoplasms | 2 | 2025 | 48 | 0.430 |
Why?
| | Robotic Surgical Procedures | 2 | 2015 | 210 | 0.430 |
Why?
| | Adenoma | 1 | 2016 | 210 | 0.420 |
Why?
| | Neurofibromatosis 1 | 2 | 2019 | 59 | 0.420 |
Why?
| | Societies, Medical | 5 | 2025 | 907 | 0.410 |
Why?
| | Prostatic Neoplasms | 2 | 2019 | 972 | 0.410 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2012 | 2240 | 0.400 |
Why?
| | Hypertension | 1 | 2022 | 1272 | 0.400 |
Why?
| | Acute-Phase Proteins | 1 | 2013 | 66 | 0.390 |
Why?
| | Lipocalins | 1 | 2013 | 35 | 0.390 |
Why?
| | Germ-Line Mutation | 3 | 2025 | 180 | 0.390 |
Why?
| | Minimally Invasive Surgical Procedures | 4 | 2025 | 196 | 0.380 |
Why?
| | Ultrasonography | 5 | 2019 | 788 | 0.380 |
Why?
| | Databases, Factual | 5 | 2019 | 1493 | 0.380 |
Why?
| | Ovarian Neoplasms | 3 | 2021 | 604 | 0.370 |
Why?
| | Radiation Protection | 1 | 2013 | 41 | 0.370 |
Why?
| | United States | 16 | 2026 | 16136 | 0.370 |
Why?
| | Infertility | 2 | 2024 | 62 | 0.370 |
Why?
| | Patient Education as Topic | 1 | 2018 | 770 | 0.370 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2013 | 100 | 0.360 |
Why?
| | Combined Modality Therapy | 5 | 2025 | 1271 | 0.360 |
Why?
| | Biopsy, Needle | 1 | 2013 | 183 | 0.360 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2016 | 499 | 0.360 |
Why?
| | Glucose Transporter Type 1 | 1 | 2012 | 49 | 0.350 |
Why?
| | Carcinoma, Medullary | 2 | 2025 | 16 | 0.350 |
Why?
| | Multimodal Imaging | 1 | 2013 | 137 | 0.340 |
Why?
| | Multivariate Analysis | 5 | 2018 | 1543 | 0.340 |
Why?
| | Neoplasm Metastasis | 5 | 2019 | 693 | 0.340 |
Why?
| | Codon | 1 | 2011 | 92 | 0.330 |
Why?
| | Primary Prevention | 1 | 2013 | 222 | 0.330 |
Why?
| | Incidence | 7 | 2019 | 2936 | 0.330 |
Why?
| | Proline | 1 | 2011 | 79 | 0.330 |
Why?
| | Positron-Emission Tomography | 1 | 2013 | 343 | 0.330 |
Why?
| | Clinical Trials as Topic | 2 | 2026 | 1064 | 0.320 |
Why?
| | Seasons | 1 | 2013 | 540 | 0.310 |
Why?
| | Vena Cava, Inferior | 1 | 2011 | 80 | 0.310 |
Why?
| | Suburethral Slings | 1 | 2010 | 10 | 0.310 |
Why?
| | Temperature | 1 | 2013 | 635 | 0.310 |
Why?
| | Arginine | 1 | 2011 | 264 | 0.310 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 616 | 0.300 |
Why?
| | Sex Factors | 3 | 2024 | 2107 | 0.300 |
Why?
| | Hernia, Ventral | 1 | 2010 | 33 | 0.300 |
Why?
| | Urinary Incontinence | 1 | 2010 | 65 | 0.300 |
Why?
| | Urinary Bladder, Neurogenic | 1 | 2010 | 46 | 0.300 |
Why?
| | Creatinine | 2 | 2026 | 511 | 0.300 |
Why?
| | Mouth Mucosa | 1 | 2009 | 84 | 0.290 |
Why?
| | Ureter | 4 | 2014 | 37 | 0.290 |
Why?
| | Campomelic Dysplasia | 1 | 2009 | 2 | 0.290 |
Why?
| | Dysgerminoma | 1 | 2009 | 6 | 0.290 |
Why?
| | Urethra | 2 | 2011 | 55 | 0.290 |
Why?
| | Skin Transplantation | 1 | 2009 | 77 | 0.290 |
Why?
| | Angiogenesis Inhibitors | 1 | 2011 | 239 | 0.290 |
Why?
| | Urolithiasis | 1 | 2009 | 11 | 0.290 |
Why?
| | Clitoris | 1 | 2009 | 9 | 0.290 |
Why?
| | SOX9 Transcription Factor | 1 | 2009 | 27 | 0.280 |
Why?
| | Length of Stay | 4 | 2025 | 1358 | 0.280 |
Why?
| | Brachytherapy | 2 | 2021 | 132 | 0.280 |
Why?
| | Recovery of Function | 1 | 2013 | 725 | 0.280 |
Why?
| | Bone Neoplasms | 1 | 2011 | 272 | 0.280 |
Why?
| | Venous Thrombosis | 1 | 2011 | 199 | 0.280 |
Why?
| | Surgical Flaps | 1 | 2009 | 140 | 0.270 |
Why?
| | Time Factors | 8 | 2019 | 7109 | 0.270 |
Why?
| | Attitude of Health Personnel | 1 | 2016 | 1219 | 0.270 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 866 | 0.260 |
Why?
| | Aged | 12 | 2025 | 26432 | 0.250 |
Why?
| | Calcinosis | 1 | 2009 | 231 | 0.250 |
Why?
| | Neuroblastoma | 2 | 2025 | 177 | 0.250 |
Why?
| | Middle Aged | 14 | 2025 | 36619 | 0.240 |
Why?
| | Nerve Growth Factor | 1 | 2026 | 36 | 0.240 |
Why?
| | Health Promotion | 1 | 2013 | 786 | 0.240 |
Why?
| | Risk Factors | 8 | 2018 | 10921 | 0.240 |
Why?
| | Ureterocele | 2 | 2016 | 7 | 0.230 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2026 | 155 | 0.220 |
Why?
| | Vesico-Ureteral Reflux | 2 | 2016 | 38 | 0.220 |
Why?
| | Postoperative Complications | 6 | 2025 | 3034 | 0.220 |
Why?
| | Mitotic Index | 2 | 2015 | 24 | 0.220 |
Why?
| | Biomarkers, Tumor | 3 | 2025 | 1339 | 0.220 |
Why?
| | Carcinoma, Papillary | 1 | 2025 | 83 | 0.220 |
Why?
| | Kidney Diseases | 1 | 2009 | 428 | 0.210 |
Why?
| | Hypertrophy | 2 | 2019 | 127 | 0.210 |
Why?
| | Antineoplastic Agents | 3 | 2025 | 2219 | 0.210 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 983 | 0.210 |
Why?
| | Genetic Predisposition to Disease | 5 | 2025 | 2488 | 0.210 |
Why?
| | Perioperative Care | 2 | 2024 | 235 | 0.210 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2013 | 429 | 0.200 |
Why?
| | Adenosine Triphosphate | 1 | 2026 | 494 | 0.200 |
Why?
| | Clinical Competence | 2 | 2025 | 1272 | 0.190 |
Why?
| | Gonadal Dysgenesis | 1 | 2023 | 6 | 0.190 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2024 | 70 | 0.190 |
Why?
| | Adrenocortical Carcinoma | 1 | 2024 | 72 | 0.190 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2024 | 178 | 0.190 |
Why?
| | Lymphocytes | 1 | 2025 | 379 | 0.190 |
Why?
| | Tumor Suppressor Proteins | 1 | 2025 | 315 | 0.190 |
Why?
| | Mast Cells | 1 | 2024 | 150 | 0.190 |
Why?
| | Pubic Bone | 1 | 2022 | 6 | 0.180 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2025 | 429 | 0.180 |
Why?
| | Monocytes | 1 | 2025 | 538 | 0.180 |
Why?
| | Urination | 1 | 2022 | 46 | 0.170 |
Why?
| | Algorithms | 1 | 2009 | 1849 | 0.170 |
Why?
| | Blood Platelets | 1 | 2025 | 382 | 0.170 |
Why?
| | Sertoli Cell Tumor | 1 | 2021 | 1 | 0.170 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2022 | 118 | 0.170 |
Why?
| | Biomarkers | 3 | 2026 | 4340 | 0.170 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2021 | 28 | 0.170 |
Why?
| | Aniridia | 1 | 2020 | 5 | 0.160 |
Why?
| | Diagnosis, Differential | 3 | 2019 | 1503 | 0.160 |
Why?
| | PAX6 Transcription Factor | 1 | 2020 | 21 | 0.160 |
Why?
| | Testosterone | 2 | 2015 | 419 | 0.160 |
Why?
| | Interleukin-2 | 1 | 2022 | 434 | 0.160 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2021 | 47 | 0.160 |
Why?
| | Pneumothorax | 1 | 2021 | 54 | 0.160 |
Why?
| | Codon, Nonsense | 1 | 2020 | 46 | 0.160 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2019 | 122 | 0.160 |
Why?
| | Feasibility Studies | 3 | 2026 | 1135 | 0.160 |
Why?
| | Eye Proteins | 1 | 2020 | 93 | 0.160 |
Why?
| | Reoperation | 3 | 2014 | 645 | 0.160 |
Why?
| | Priapism | 1 | 2019 | 9 | 0.150 |
Why?
| | Penile Neoplasms | 1 | 2019 | 7 | 0.150 |
Why?
| | Syndrome | 1 | 2021 | 380 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2024 | 2022 | 0.150 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2019 | 44 | 0.150 |
Why?
| | Patient Selection | 3 | 2013 | 728 | 0.150 |
Why?
| | Myosin-Light-Chain Kinase | 1 | 2019 | 19 | 0.150 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2019 | 8 | 0.150 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2019 | 10 | 0.150 |
Why?
| | Proportional Hazards Models | 3 | 2011 | 1331 | 0.140 |
Why?
| | Neutrophils | 1 | 2025 | 1133 | 0.140 |
Why?
| | Decision Trees | 1 | 2019 | 76 | 0.140 |
Why?
| | Computers | 1 | 2019 | 66 | 0.140 |
Why?
| | Puberty, Precocious | 1 | 2019 | 12 | 0.140 |
Why?
| | Genotype | 2 | 2016 | 1879 | 0.140 |
Why?
| | Dermatofibrosarcoma | 1 | 2018 | 7 | 0.140 |
Why?
| | Hospitals | 1 | 2023 | 738 | 0.140 |
Why?
| | Genetic Testing | 2 | 2019 | 492 | 0.140 |
Why?
| | Self-Examination | 1 | 2018 | 1 | 0.140 |
Why?
| | Diagnostic Errors | 1 | 2019 | 178 | 0.130 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 238 | 0.130 |
Why?
| | Proton Therapy | 1 | 2018 | 16 | 0.130 |
Why?
| | Animals | 6 | 2025 | 38107 | 0.130 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 222 | 0.130 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 196 | 0.130 |
Why?
| | Analysis of Variance | 2 | 2017 | 1298 | 0.130 |
Why?
| | Mutation | 1 | 2009 | 4093 | 0.130 |
Why?
| | Preoperative Period | 1 | 2018 | 157 | 0.130 |
Why?
| | Asymptomatic Diseases | 1 | 2018 | 102 | 0.130 |
Why?
| | Drug Utilization | 1 | 2018 | 171 | 0.130 |
Why?
| | Aged, 80 and over | 4 | 2019 | 8391 | 0.130 |
Why?
| | Unnecessary Procedures | 1 | 2017 | 56 | 0.130 |
Why?
| | Testis | 1 | 2018 | 158 | 0.130 |
Why?
| | Registries | 3 | 2025 | 2400 | 0.130 |
Why?
| | Ultrasonography, Doppler | 1 | 2018 | 122 | 0.130 |
Why?
| | Pancreatic Neoplasms | 1 | 2025 | 944 | 0.120 |
Why?
| | Intraoperative Period | 1 | 2017 | 69 | 0.120 |
Why?
| | Europe | 1 | 2018 | 421 | 0.120 |
Why?
| | General Surgery | 1 | 2019 | 217 | 0.120 |
Why?
| | Logistic Models | 3 | 2018 | 2126 | 0.120 |
Why?
| | Mice | 3 | 2024 | 18297 | 0.120 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1244 | 0.120 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2025 | 1408 | 0.120 |
Why?
| | Feminization | 1 | 2015 | 6 | 0.120 |
Why?
| | North America | 1 | 2016 | 300 | 0.110 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 355 | 0.110 |
Why?
| | Certification | 1 | 2016 | 118 | 0.110 |
Why?
| | Translocation, Genetic | 2 | 2018 | 127 | 0.110 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 503 | 0.110 |
Why?
| | Models, Statistical | 1 | 2019 | 669 | 0.110 |
Why?
| | Learning | 1 | 2019 | 446 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1591 | 0.110 |
Why?
| | Phosphorylation | 1 | 2019 | 1724 | 0.110 |
Why?
| | History, 21st Century | 1 | 2015 | 224 | 0.110 |
Why?
| | Anaplasia | 2 | 2024 | 7 | 0.100 |
Why?
| | Matched-Pair Analysis | 1 | 2014 | 38 | 0.100 |
Why?
| | Forecasting | 1 | 2016 | 388 | 0.100 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2014 | 18 | 0.100 |
Why?
| | Genitalia, Female | 1 | 2014 | 43 | 0.100 |
Why?
| | TRPM Cation Channels | 1 | 2014 | 74 | 0.100 |
Why?
| | Ureteral Calculi | 1 | 2014 | 15 | 0.100 |
Why?
| | Kidney Function Tests | 1 | 2014 | 156 | 0.100 |
Why?
| | Inflammation | 1 | 2025 | 2919 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 426 | 0.100 |
Why?
| | Disease Management | 1 | 2017 | 651 | 0.100 |
Why?
| | Lipocalin-2 | 1 | 2013 | 80 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2020 | 947 | 0.090 |
Why?
| | Estrogens | 1 | 2015 | 364 | 0.090 |
Why?
| | Blood Vessels | 1 | 2014 | 164 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 3926 | 0.090 |
Why?
| | Tissue Array Analysis | 1 | 2012 | 49 | 0.090 |
Why?
| | Spermatic Cord | 1 | 2012 | 1 | 0.090 |
Why?
| | Monitoring, Physiologic | 1 | 2014 | 279 | 0.090 |
Why?
| | Autophagy | 1 | 2014 | 290 | 0.090 |
Why?
| | Cohort Studies | 5 | 2016 | 6077 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 197 | 0.090 |
Why?
| | Radiation Dosage | 1 | 2013 | 193 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2018 | 806 | 0.080 |
Why?
| | Fetal Diseases | 1 | 2013 | 192 | 0.080 |
Why?
| | Surgical Wound Dehiscence | 1 | 2011 | 22 | 0.080 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2011 | 70 | 0.080 |
Why?
| | Cross-Sectional Studies | 2 | 2014 | 5899 | 0.080 |
Why?
| | Thrombectomy | 1 | 2011 | 79 | 0.080 |
Why?
| | Bevacizumab | 1 | 2011 | 169 | 0.080 |
Why?
| | Compliance | 1 | 2010 | 50 | 0.080 |
Why?
| | Texas | 1 | 2011 | 280 | 0.080 |
Why?
| | Rectum | 1 | 2011 | 180 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 517 | 0.080 |
Why?
| | Sulfonamides | 1 | 2014 | 594 | 0.080 |
Why?
| | Pyrroles | 1 | 2011 | 222 | 0.070 |
Why?
| | Referral and Consultation | 1 | 2016 | 881 | 0.070 |
Why?
| | Muscle, Smooth | 1 | 2010 | 152 | 0.070 |
Why?
| | Penis | 2 | 2019 | 33 | 0.070 |
Why?
| | Operative Time | 3 | 2014 | 195 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1031 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 790 | 0.070 |
Why?
| | Internship and Residency | 1 | 2019 | 1281 | 0.070 |
Why?
| | Radiography | 1 | 2011 | 861 | 0.070 |
Why?
| | Remission, Spontaneous | 2 | 2021 | 39 | 0.070 |
Why?
| | Alleles | 1 | 2011 | 907 | 0.070 |
Why?
| | Pilot Projects | 1 | 2014 | 1888 | 0.070 |
Why?
| | MicroRNAs | 1 | 2014 | 699 | 0.070 |
Why?
| | Congenital Abnormalities | 1 | 2008 | 108 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2113 | 0.060 |
Why?
| | Indoles | 1 | 2011 | 511 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2014 | 3647 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2012 | 589 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2921 | 0.060 |
Why?
| | Pregnancy | 1 | 2018 | 7230 | 0.060 |
Why?
| | Signal Transduction | 1 | 2019 | 5246 | 0.060 |
Why?
| | Cystoscopy | 2 | 2016 | 21 | 0.060 |
Why?
| | Nephroma, Mesoblastic | 1 | 2025 | 2 | 0.060 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2024 | 15 | 0.050 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 992 | 0.050 |
Why?
| | Image-Guided Biopsy | 1 | 2024 | 41 | 0.050 |
Why?
| | Adrenalectomy | 1 | 2024 | 68 | 0.050 |
Why?
| | Nephroureterectomy | 1 | 2023 | 2 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1512 | 0.050 |
Why?
| | Sexual Development | 1 | 2023 | 17 | 0.050 |
Why?
| | Gonads | 1 | 2023 | 23 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 350 | 0.050 |
Why?
| | Lymphoma | 1 | 2024 | 251 | 0.050 |
Why?
| | Pancreatectomy | 1 | 2025 | 289 | 0.050 |
Why?
| | Analgesics, Opioid | 2 | 2024 | 1221 | 0.040 |
Why?
| | Germany | 1 | 2020 | 139 | 0.040 |
Why?
| | Accreditation | 1 | 2019 | 100 | 0.040 |
Why?
| | Hyperplasia | 1 | 2019 | 164 | 0.040 |
Why?
| | Mohs Surgery | 1 | 2018 | 30 | 0.030 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2018 | 28 | 0.030 |
Why?
| | Liver Neoplasms | 1 | 2024 | 776 | 0.030 |
Why?
| | Mosaicism | 1 | 2017 | 67 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2018 | 334 | 0.030 |
Why?
| | Ureteroscopy | 1 | 2016 | 16 | 0.030 |
Why?
| | Monitoring, Intraoperative | 1 | 2016 | 66 | 0.030 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2014 | 19 | 0.030 |
Why?
| | Caveolin 1 | 1 | 2014 | 20 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 568 | 0.030 |
Why?
| | Ureterostomy | 1 | 2014 | 3 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 238 | 0.030 |
Why?
| | Oncogenes | 1 | 2014 | 113 | 0.030 |
Why?
| | Bone Marrow Neoplasms | 1 | 2013 | 4 | 0.020 |
Why?
| | Cicatrix | 1 | 2014 | 72 | 0.020 |
Why?
| | Organ Size | 1 | 2014 | 465 | 0.020 |
Why?
| | Mice, Nude | 1 | 2014 | 668 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 472 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2014 | 750 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2011 | 28 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2011 | 313 | 0.020 |
Why?
| | Area Under Curve | 1 | 2011 | 335 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1998 | 0.020 |
Why?
| | Gene Silencing | 1 | 2011 | 200 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 3200 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 396 | 0.020 |
Why?
| | Dihydrolipoamide Dehydrogenase | 1 | 2009 | 6 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1432 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 3545 | 0.020 |
Why?
|
|
Cost's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|